As a nuclear antigen, Ki‐67 is expressed in the G1, S, and G2 phases of the cell cycle and is an established proliferation marker in breast cancer.24 A recent study demonstrated that a decrease in the Ki‐67 index after treatment indicates effective neoadjuvant chemotherapy and better prognosis.25 Compared with the control group, the Ki‐67 index in the paclitaxel group and combination group was significantly decreased (P = 0.03 and P = 0.0003, respectively; Figure 3A), whereas no significant reduction was noted in the AAV2‐VEGF‐Trap group (P = 0.31). The gene discussed is MKI67; the disease is breast carcinoma.